Cover Image
市場調查報告書

復發惡性神經膠母細胞瘤:開發平台分析

Recurrent Malignant Glioma - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 247796
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
復發惡性神經膠母細胞瘤:開發平台分析 Recurrent Malignant Glioma - Pipeline Review, H2 2015
出版日期: 2015年07月29日 內容資訊: 英文 61 Pages
簡介

復發惡性神經膠母細胞瘤定義為治療後復發的腫瘤。治療方法包含化療和放射線治療等。

本報告提供復發惡性神經膠母細胞瘤的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

復發惡性神經膠母細胞瘤概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Amgen Inc.
  • AstraZeneca Plc
  • Eisai
  • MediGene AG
  • Tiziana Life Sciences Plc
  • ZIOPHARM Oncology, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Ad-RTS-IL-12
  • Carboxyamidotriazole Orotate
  • Cell Therapy for Refractory Gliomas
  • Cell Therapy to Target IL-13 for Malignant Glioma
  • Dendritic Cell Therapy for Oncology
  • Dendritic Cell Therapy for Recurrent Malignant Glioma
  • disufenton sodium
  • DNX-2401
  • G-207
  • irofulven
  • milciclib
  • rilotumumab

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6884IDB

Summary

Global Markets Direct's, 'Recurrent Malignant Glioma - Pipeline Review, H2 2015', provides an overview of the Recurrent Malignant Glioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Malignant Glioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Recurrent Malignant Glioma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Recurrent Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Recurrent Malignant Glioma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Recurrent Malignant Glioma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Recurrent Malignant Glioma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Recurrent Malignant Glioma Overview
  • Therapeutics Development
    • Pipeline Products for Recurrent Malignant Glioma - Overview
    • Pipeline Products for Recurrent Malignant Glioma - Comparative Analysis
  • Recurrent Malignant Glioma - Therapeutics under Development by Companies
  • Recurrent Malignant Glioma - Therapeutics under Investigation by Universities/Institutes
  • Recurrent Malignant Glioma - Pipeline Products Glance
    • Clinical Stage Products
  • Recurrent Malignant Glioma - Products under Development by Companies
  • Recurrent Malignant Glioma - Products under Investigation by Universities/Institutes
  • Recurrent Malignant Glioma - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • AstraZeneca Plc
    • Eisai Co., Ltd.
    • MediGene AG
    • Tiziana Life Sciences Plc
    • ZIOPHARM Oncology, Inc.
  • Recurrent Malignant Glioma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Ad-RTS-IL-12 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Carboxyamidotriazole Orotate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy for Refractory Gliomas - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Target IL-13 for Malignant Glioma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Dendritic Cell Therapy for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Dendritic Cell Therapy for Recurrent Malignant Glioma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • disufenton sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DNX-2401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • G-207 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • irofulven - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • milciclib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rilotumumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Recurrent Malignant Glioma - Recent Pipeline Updates
  • Recurrent Malignant Glioma - Dormant Projects
  • Recurrent Malignant Glioma - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Recurrent Malignant Glioma, H2 2015
  • Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Recurrent Malignant Glioma - Pipeline by Amgen Inc., H2 2015
  • Recurrent Malignant Glioma - Pipeline by AstraZeneca Plc, H2 2015
  • Recurrent Malignant Glioma - Pipeline by Eisai Co., Ltd., H2 2015
  • Recurrent Malignant Glioma - Pipeline by MediGene AG, H2 2015
  • Recurrent Malignant Glioma - Pipeline by Tiziana Life Sciences Plc, H2 2015
  • Recurrent Malignant Glioma - Pipeline by ZIOPHARM Oncology, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Recurrent Malignant Glioma Therapeutics - Recent Pipeline Updates, H2 2015
  • Recurrent Malignant Glioma - Dormant Projects, H2 2015
  • Recurrent Malignant Glioma - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Recurrent Malignant Glioma, H2 2015
  • Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top